SLC27A3 and glioblastoma: Treating GBM neurosphere cells with either of the differentiating agent all-trans retinoic acid (RA) or the histone deacetylace inhibitor trichostatin A (TSA) [21,25] also resulted in significant reductions (by 50-75%) in ACSVL3 protein levels (Figure 1C).